Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801) (Q85646462)
Jump to navigation
Jump to search
scientific article published on 05 September 2013
Language | Label | Description | Also known as |
---|---|---|---|
English | Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801) |
scientific article published on 05 September 2013 |
Statements
Sorafenib and bevacizumab combination targeted therapy in advanced neuroendocrine tumour: a phase II study of Spanish Neuroendocrine Tumour Group (GETNE0801) (English)
Daniel Castellano
Jaume Capdevila
Javier Sastre
Vicente Alonso
Marta Llanos
José Luis Manzano Mozo
Isabel Sevilla
Ignacio Durán
5 September 2013